Jpmorgan Chase & CO Paratek Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$1.52 - $2.8 $302,317 - $556,900	198,893 Added 7250.93%	201,636 $445,000
Q1 2023 May 11, 2023	BUY	$1.37 - $2.54 $1,516 - $2,811	1,107 Added 67.67%	2,743 $6,000
Q4 2022 Feb 13, 2023	SELL	$1.67 - $2.51 $3,877 - $5,828	-2,322 Reduced 58.67%	1,636 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $2.93 $3,714 - $5,552	1,895 Added 91.86%	3,958 $10,000
Q2 2022 Aug 11, 2022	SELL	$1.73 - $3.09 $46,507 - $83,068	-26,883 Reduced 92.87%	2,063 $4,000
Q1 2022 May 11, 2022	BUY	$2.94 - $4.77 $19,101 - $30,990	6,497 Added 28.94%	28,946 $86,000
Q4 2021 Feb 10, 2022	BUY	$4.07 - $5.3 $4,525 - $5,893	1,112 Added 5.21%	22,449 $101,000
Q3 2021 Nov 12, 2021	BUY	$4.7 - $7.24 $100,283 - $154,479	21,337 New	21,337 $103,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.